Global Vaccine Market Report 2022

Make PDF

Key highlights of the report-

• This is the first report to capture the implications of COVID-19 for vaccine markets. 
• As per the report, critical vaccines in demand by high-income countries continue to be in short supply for low-income countries.
• Decades-long progress in development, supply and access to doses remains overshadowed by an unfavourable environment.
• The burden of cervical cancer is higher in low-income countries in spite of which the human papillomavirus vaccine has been introduced only in 41 percent of these countries. 
• In comparison, 83 percent of high-income countries have access to the HPV vaccine.
• The right to health includes the right to vaccines, this new report shows that free-market dynamics deprive some of the world’s poorest and most vulnerable people of that right.
• The COVID-19 vaccine accounted for most of the 16 billion vaccine doses, worth $141 billion, supplied in 2021.
• This was a major push for the market — with the volume rising three-fold compared to 2019 and nearly three-and-a-half times the 2019 market value.
• More than 90 manufacturers were supplying vaccines to WHO member states across the world in 2021. 
• However, less than 10 managed a bulk of the supply due to “broad portfolios, global reach and a diversity of deployable technology.”
• Only two manufacturers are supplying key vaccines such as pneumococcal vaccines, measles and rubella-containing vaccines across the world.
• Policies and supply chains in specific regions dictate access to vaccines, due to which the African and eastern Mediterranean regions fare the worst.
• These regions rely on international manufacturers for 90 per cent of their procured vaccines.
• The Global Vaccine Market Report listed possible changes which can be made to initiate a paradigm shift in the vaccine market. 
• These include: “clear immunisation plans and more aggressive investment and stronger oversight of vaccine development, production and distribution.”

Make PDF